Pfizer PFE, -1.41% presented its case against the federal government Tuesday in a lawsuit that could shake up drug pricing as well as the government’s anti-fraud enforcement efforts.

In oral arguments before the U.S. District Court for the Southern District of New York, the pharmaceutical giant sought a ruling in favor of proposed programs that would let the company help cover copays for Medicare patients taking tafamidis, a $225,000-a-year cardiovascular drug.

Pfizer argues its case in federal court for helping seniors meet drug copays